Alex Blyth is a British biotech entrepreneur, biologist, and economist with over 20 years of experience in developing innovative healthcare solutions. He founded LIfT BioSciences in 2016 after the loss of his mother to pancreatic cancer, aiming to revolutionize cancer treatment through the development of neutrophil-based immunotherapies. Under his leadership, LIfT has pioneered the N-LIfT platform, producing Immuno-Modulatory Alpha Neutrophils (IMANs) designed to overcome tumor resistance and stimulate durable immune responses in solid tumors. Prior to LIfT, Alex contributed to the development and commercialization of several first-in-class biopharmaceuticals, including T-Vec, Erbitux, and Abraxane. He has held strategic roles at Cello Health Consulting and Cambridge Consultants, and founded ventures such as NGX (Nutri-Genetix) and The Mission Fund, focusing on personalized nutrition and early-stage biotech investments, respectively. Alex holds degrees in Economics from the University of Southampton and Biological Sciences from The Open University, along with executive education from Oxford Saïd Business School.Driven by a mission to develop affordable, curative therapies, Alex continues to lead LIfT BioSciences toward clinical trials and global partnerships, aiming to transform the landscape of cancer treatment.